engasertib

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

A blood test for tuberculosis that can distinguish between dormant and active infections has shown promise in a clinical trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.